share_log

Reported Sunday, Arrowhead Pharmaceuticals Announces New Phase 2 Data Of Plozasiran Published In JAMA Cardiology And Presented At ACC.24

Moomoo 24/7 ·  Apr 8 02:54
  • - Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
  • - SHASTA-3 and SHASTA-4 Phase 3 studies to be initiated
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment